Skip to main content

Table 2 Proportions of patients with plasma HIV-1 RNA < 50 copies/mL and < 400 copies/mL at week 48

From: Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study

 

Naïve (N = 27)

Restart (N = 30)

Switch (N = 10)

Total (N = 67)

< 50 copies/mL (ITT M = F)

    

n/N (%)

7/27 (26)

11/30 (37)

5/10 (50)

23/67 (34)

95% confidence interval1

[11-46]

[20-56]

[19-81]

[23-47]

< 50 copies/mL (ITT M = E)

    

n/N (%)

7/16 (44)

11/19 (58)

5/6 (83)

23/41 (56)

95% confidence interval1

[20-70]

[34-80]

[36-100]

[40-72]

< 400 copies/mL (ITT M = F)

    

n/N (%)

15/27 (56)

16/30 (53)

6/10 (60)

37/67 (55)

95% confidence interval1

[35-75]

[34-72]

[26-88]

[43-67]

< 400 copies/mL (ITT M = E)

    

n/N (%)

15/16 (94)

16/19 (84)

6/6 (100)

37/41 (90)

95% confidence interval1

[70-100]

[60-97]

[54-100]

[77-97]

  1. ITT (M = F) = intent-to-treat missing equals failure analysis; ITT (M = E) = intent-to-treat missing equals excluded analysis
  2. 1Confidence interval on the percentage